

**Medicaid Preferred Drug List (PDL) Program:  
Round 1 Annual Drug Class Review  
Pharmacy and Therapeutics Committee Meeting  
Monday, August 23, 2004  
9:00 a.m., DMAS Board Room  
DRAFT AGENDA**

- **Welcome and Introductions** Patrick W. Finnerty, Director
- **Comments from the Secretary of Health and Human Resources** The Honorable Jane H. Woods, Secretary of Health and Human Resources
- **Comments from the Chairperson** Randy Axelrod, M.D., Chairman
- **Acceptance of Minutes from April 21, 2004 Meeting** P&T Committee Members
- **Drug Class Discussions for Round 1 Annual Review** P&T Committee Members
  - Angiotensin Converting Enzyme Inhibitors
  - (ACE Inhibitors)
  - Angiotensin II Receptor Blocking Agents (ARBs)
  - Beta Adrenergics
  - Beta Blockers
  - Calcium Channel Blockers
  - H2 Antagonists
  - HMG CoA Reductase Inhibitors (Statins)
  - Inhaled Corticosteroids
  - Nasal Steroids
  - Proton Pump Inhibitors (PPIs)
  - Second Generation Antihistamines (LSAs)
  - Sedative Hypnotics
  - Selective Cox-2 Inhibitors and NSAIDS
- **Confidential Meeting** Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information
- **Criteria Discussions for Round 1 Annual Review** P&T Committee Members
- **P&T Committee Discussion** Randy Axelrod, M.D.  
P&T Committee Members
- **Open Issues** Randy Axelrod, M.D., Chairman
  - Product Availability Guidance
- **Next Meeting – September 20, 2004, 9:00 a.m.** Randy Axelrod, M.D., Chairman

**Oral presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on the specific drug classes that are listed on the Agenda. All presentations must be clinical in nature and based on scientific material. No anecdotal accounts are to be given. Each speaker will be allocated to a 3 - 5 minutes time slot. The actual speakers and number of speakers will be decided by the Chairperson based on relevancy of the information.

If you are interested in providing specific clinical drug information, please submit your written comments or an outline of discussion points, indicate your request to speak at the meeting and the name of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by COB **Friday, July 23, 2004.**

**Written information/presentations:** The P&T Committee will accept written comments for consideration. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by COB **Friday, July 23, 2004.**